Photobiomodulation therapy prevents dysgeusia chemotherapy induced in breast cancer women treated with doxorubicin plus cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical trial

Photobiomodulation therapy prevents dysgeusia chemotherapy induced in breast cancer women treated with doxorubicin plus cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical trial

Purpose To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC). Methods This is a phase II, randomized, triple-blind, placebo-controlled clinical trial involving 112 breast cancer patients treated wi...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer Vol. 30; no. 3; pp. 2569 - 2580
Main Authors: Malta, Cássia Emanuella Nóbrega, Carlos, Anna Clara Aragão Matos, de Alencar, Manuele Carine Maciel, Alves e Silva, Eveline Fernandes, Nogueira, Victor Bruno Caitano, Alves, Ana Paula Negreiros Nunes, Chaves, Fábio Figueiredo, de Moura, José Fernando Bastos, de Barros Silva, Paulo Goberlânio
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-03-2022
Springer Nature B.V
Subjects:
Antineoplastic Agents
Breast cancer
Breast Neoplasms - drug therapy
Cancer therapies
Chemotherapy
Clinical trials
Cyclophosphamide - adverse effects
Doxorubicin - adverse effects
Dysgeusia - chemically induced
Dysgeusia - epidemiology
Female
Humans
Light therapy
Low-Level Light Therapy
Medicine
Medicine & Public Health
Nursing
Nursing Research
Oncology
Original Article
Pain Medicine
Quality of Life
Rehabilitation Medicine
Side effects
Taste
Taste disorders
Womens health
Anthracyclines
Cyclophosphamide
Low-intensity light therapy
Dysgeusia
Breast neoplasm
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC). Methods This is a phase II, randomized, triple-blind, placebo-controlled clinical trial involving 112 breast cancer patients treated with AC. The patients were divided equally into two groups: a test group treated with 2 J red laser and 3 J infrared laser on 21 points that were symmetrically distributed on the tongue on day 0 of four cycles of AC, and an equal placebo group treated with simulated PBMT to blind the patient, evaluator, and statistician. The clinicopathological and sociodemographic data, results of taste test, and subjective taste analysis, and the QoL, ECOG performance status, body mass index, and other side effects were recorded. The data were analyzed using ANOVA-RM/Bonferroni, Friedman/Dunn, and chi-square/Fisher’s exact tests. Results PBMT patients showed less objective and subjective taste loss ( p <0.05). On the other hand, the placebo group showed a higher ECOG status ( p =0.037) and more significant weight loss ( p <0.001) after four cycles of AC. The QoL was significantly higher in the PBMT group ( p <0.05) at all assessment periods, and PBMT treatment also reduced the incidence of cachexia ( p =0.020), anorexia ( p <0.001), diarrhea ( p =0.040), oral mucositis ( p =0.020), and vomiting ( p =0.008). Conclusion PBMT reduced the taste loss and improved the overall health status and QoL of patients with breast cancer treated with AC. Trial registration Brazilian Clinical Trials Registry ( www.ensaiosclinicos.gov.br ) approval number RBR-9qnm34y, registered on 01/05/2021
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-021-06642-7